| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Eltrombopag |
| Brand | Revolade® |
| Indication | For adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy |
| Assessment Process | |
| Rapid review commissioned | 10/01/2014 |
| Rapid review completed | 13/02/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended. |